Introducing Verisante Aura™, a revolutionary non-invasive Raman spectroscopy system designed to aid medical professionals in the detection of skin cancer. The system provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in less than a second.
Verisante Aura™ was designed to assist medical professionals in the detection of skin cancer by allowing rapid scanning of multiple skin lesions on at-risk individuals. Scans can be accomplished quickly and accurately and can improve patient experience by helping avoid unnecessary biopsies. Not only does Aura™ have the ability to dramatically speed up the diagnostic process, it has been proven to have a remarkably high sensitivity to detect skin cancer, thereby assisting doctors in detecting skin cancer in its early, most easily treatable stages.
Jointly developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions.
Tested at the renowned Vancouver General Hospital Skin Care Centre, the results published in 2012 showed that Aura™ can operate at 99% diagnostic sensitivity for differentiating malignant and premalignant skin lesions from benign ones, and reduce the number of unnecessary biopsies by 50%–100%.*
*Harvey Lui, Jianhua Zhao, David McLean, et al, Real-time Raman Spectroscopy for In Vivo Skin Cancer Diagnosis. Cancer Res 2012;72:2491-2500. Published OnlineFirst March 20, 2012.